Enhanced Levels of Glycosphingolipid GM3 Delay the Progression of Diabetic Nephropathy
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241411355 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Shokichi Naito und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami, Sagamihara 252-0374, Kanagawa, Japan. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental, Podocytes, Diabetes Mellitus. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
We recently found that albuminuria levels in patients with minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) inversely correlate with glycosphingolipid GM3 expression levels in glomerular podocytes. Moreover, we showed enhanced expression of GM3 via activation of the GM3 synthase gene upon administration of valproic acid (VPA) is effective in suppressing albuminuria and podocyte injury in mice with anti-nephrin antibody-induced podocytopathy. However, the therapeutic effect of GM3 on diabetic nephropathy, which is the most common underlying disease in patients undergoing dialysis and with podocyte injury, remains unclear. Here, we investigated the therapeutic effect of enhanced GM3 expression via VPA on podocyte injury using streptozotocin-induced diabetic nephropathy model mice. Administration of VPA clearly decreased levels of albuminuria and glomerular lesions and inhibited the loss of podocytes and expansion in the mesangial area. Furthermore, we found that albuminuria levels in patients with diabetic nephropathy inversely correlate with the expression of GM3 in podocytes. These results indicate that maintaining GM3 expression in podocytes by administration of VPA may be effective in treating not only podocyte injury, such as MCD and FSGS, but also the late stage of diabetic nephropathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami, Sagamihara 252-0374, Kanagawa, Japan.
- National Institute of Advanced Industrial Science and Technology (AIST), 1-1-1 Umezono, Tsukuba 305-8560, Ibaraki, Japan.
Förderung
- JSPS KAKENHI
Zitieren
APA
Naito, S., Nakayama, K., & Kawashima, N. (2023). Enhanced Levels of Glycosphingolipid GM3 Delay the Progression of Diabetic Nephropathy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241411355
Vancouver
Naito S, Nakayama K, Kawashima N. Enhanced Levels of Glycosphingolipid GM3 Delay the Progression of Diabetic Nephropathy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241411355
BibTeX
@article{Naito2023,
author = {Naito, Shokichi and Nakayama, Kenichi and Kawashima, Nagako},
title = {Enhanced Levels of Glycosphingolipid GM3 Delay the Progression of Diabetic Nephropathy},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241411355}
}
EUVIMED